Analysis of external dose rate attenuation and its related factors in differentiated thyroid carcinoma patients following I-131 therapy

对接受碘-131治疗的分化型甲状腺癌患者进行外照射剂量率衰减及其相关因素的分析

阅读:1

Abstract

BACKGROUND: Monitoring the external dose rate (EDR) attenuation serves as a key consideration in supporting discharge decisions for patients with differentiated thyroid cancer (DTC) who have undergone radioiodine therapy. We aimed to study the EDR attenuation and its related factors in DTC patients during I-131 therapy. METHODS: This study enrolled 886 DTC patients who first underwent I-131 therapy at the Third Bethune Hospital of Jilin University, China. We measured the EDR at approximately 2, 24, 48, and 72 h post-therapy. Two formulas were established to represent the EDR decay with time: 1) EDR =[Formula: see text] and EDR(%) = [Formula: see text], where EDR is the absolute external dose rate (µSv/h), EDR(%) is the percentage EDR relative to the initial EDR (100%), SI (speed index, μSv/h(2)) is the absolute decay rate of I-131 with the time, SI(%) (%/h) is the relative decay rate with the time, and b is a constant. RESULTS: The finally fitted SI and SI(%) from patients' data were -0.020 μSv/h(2) and -0.026%/h, respectively. EDR(%) exhibited a stronger correlation with administration time than EDR (R(2): 0.951 vs. 0.829). Body mass index (BMI), smoking, history of type 2 diabetes mellitus, Follicular Thyroid Carcinoma (FTC) subtype, increasing residual thyroid tissue grading, FT3 and Tg levels positively associated with SI. The factors negatively associated with SI were female sex, a higher N stage and a higher I-131 dose. SI(%) was positively associated with smoking history, history of type 2 diabetes mellitus, and FTC pathological subtype, and negatively with female sex and higher I-131 dose. CONCLUSIONS: EDR(%) had better correlation than EDR with I-131 administration time. The related factors for SI and SI(%) included I-131 dose, sex, BMI, thyroid cancer pathology, medical history and thyroid function. These findings provide a reference for radiation protection officers in evaluating radioactive activity during I-131 therapy.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。